Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer

被引：0
|
作者：
El-Rayes B
Shields, A.
Zalupski, M.
Bekaii-Saab, T.
Heilbrun, L.
Vaishampayan, U.
Manza, S.
机构：
[1] Karmanos Canc Ctr, Dearborn, MI USA
[2] Univ Michigan, Detroit, MI USA
[3] Ohio State Univ, Columbus, OH 43210 USA
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [41] A phase II trial of capecitabine (X) and irinotecan (I), in a biweekly schedule, for patients (Pts) with advanced/metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Gonzalez-Arenas, C
    Gonzalez-Flores, E
    Molina, M
    Muñoz, A
    Abad, G
    Garcia-Adrian, S
    Lopez, P
    Belon, J
    Perez-Manga, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 290S - 290S
  • [42] Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer
    Rudek, Michelle A.
    Dasari, Arvind
    Laheru, Daniel
    He, Ping
    Jin, Runyan
    Walker, Rosalind
    Taylor, Gretchen E.
    Jimeno, Antonio
    Donehower, Ross C.
    Hidalgo, Manuel
    Messersmith, Wells A.
    Purcell, W. Thomas
    JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 56 (08): : 966 - 973
  • [43] Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
    Emilio Bajetta
    Maria Di Bartolomeo
    Roberto Buzzoni
    Erminia Ferrario
    Katia F. Dotti
    Luigi Mariani
    Roberto Bajetta
    Arpine Gevorgyan
    Paola Venturino
    Margherita Galassi
    Cancer Chemotherapy and Pharmacology, 2009, 64
  • [44] Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients -: Results of a phase II study
    Steinbild, Simone
    Arends, Jann
    Medinger, Michael
    Haering, Brigitte
    Frost, Annette
    Drevs, Joachim
    Unger, Clemens
    Strecker, Ralph
    Hennig, Juergen
    Mross, Klaus
    ONKOLOGIE, 2007, 30 (12): : 629 - 635
  • [45] Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients
    Bajetta, Emilio
    Di Bartolomeo, Maria
    Buzzoni, Roberto
    Ferrario, Erminia
    Dotti, Katia F.
    Mariani, Luigi
    Bajetta, Roberto
    Gevorgyan, Arpine
    Venturino, Paola
    Galassi, Margherita
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 67 - 72
  • [46] Phase I/II study of irinotecan and UFT for advanced or metastatic colorectal cancer
    Mibu, R.
    Tanaka, S.
    Futami, K.
    Shimada, K.
    Hotokezaka, M.
    Nakahara, S.
    Ichimiya, H.
    Kido, H.
    Hirano, Y.
    Kashiwagi, T.
    Eguchi, T.
    Mitsuki, K.
    Mizumoto, K.
    Tanaka, M.
    ANTICANCER RESEARCH, 2007, 27 (4C) : 2673 - 2677
  • [47] A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
    Kwok, Gin Wai
    Leung, Roland Ching-Yu
    Chiu, Joanne
    Tang, Vikki
    Yau, Thomas Cheung
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Cardiovascular toxicity of capecitabine, irinotecan, and oxaliplatin in patients with advanced colorectal cancer (ACC). A Dutch Colorectal Cancer Group (DCCG) phase III study (Cairo)
    Koopman, M.
    antonini, N. F.
    mol, L.
    punt, C. J.
    ANNALS OF ONCOLOGY, 2006, 17 : 122 - 122
  • [49] Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
    Vincent, Mark D.
    Breadner, Daniel
    Soulieres, Denis
    Kerr, Ian G.
    Sanatani, Michael
    Kocha, Walter
    Klimo, Peter
    MacKenzie, Mary J.
    O'Connell, Anne
    Whiston, Frances
    Malpage, Anne S.
    Stitt, Larry
    Welch, Stephen A.
    FUTURE ONCOLOGY, 2017, 13 (09) : 777 - 786
  • [50] Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer
    Jimeno, Antonio
    Gravalos, Cristina
    Escudero, Pilar
    Sevilla, Isabel
    Eugenia Vega-Villegas, M.
    Alonso, Vicente
    Juez, Ignacio
    Garcia-Carbonero, Rocio
    Bovio, Humberto
    Colomer, Ramon
    Cortes-Funes, Hernan
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2008, 10 (01): : 52 - 57
12345